Aquilo Capital Management LLC 13D and 13G filings for Spero Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-14 11:16 am Sale | 2022-12-31 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 0 0.000% | -3,419,435 (Position Closed) | Filing |
| 2022-10-03 4:40 pm Sale | 2022-09-22 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 3,419,435 9.800% | -1,602,101 (-31.90%) | Filing |
| 2022-03-08 5:41 pm Purchase | 2022-01-18 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 5,021,536 15.500% | 57,355 (+1.16%) | Filing |
| 2022-02-14 3:54 pm Purchase | 2021-12-31 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 4,964,181 15.400% | 1,031,972 (+26.24%) | Filing |
| 2021-02-16 4:00 pm Sale | 2020-12-31 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 3,932,209 14.500% | -564,933 (-12.56%) | Filing |
| 2020-09-22 6:51 pm Purchase | 2020-09-11 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 4,497,142 17.400% | 3,342,786 (+289.58%) | Filing |
| 2020-02-13 8:22 pm Purchase | 2019-12-31 | 13G | Spero Therapeutics, Inc. SPRO | Aquilo Capital Management LLC | 1,154,356 6.000% | 122,409 (+11.86%) | Filing |